Ono Pharmaceutical (OTCMKTS:OPHLF) Releases Earnings Results, Beats Estimates By $0.11 EPS

Ono Pharmaceutical (OTCMKTS:OPHLF) posted its earnings results on Monday. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.11, Zacks reports. Ono Pharmaceutical had a net margin of 9.75% and a return on equity of 6.13%. The business had revenue of $892.70 million for the quarter, compared to analyst estimates of $727.58 million.

Ono Pharmaceutical Price Performance

Shares of OTCMKTS:OPHLF opened at $15.22 on Tuesday. The firm has a market cap of $7.15 billion, a PE ratio of 21.74 and a beta of 0.25. The company has a fifty day simple moving average of $13.65 and a 200 day simple moving average of $12.20. The company has a current ratio of 2.99, a quick ratio of 2.50 and a debt-to-equity ratio of 0.11. Ono Pharmaceutical has a 12-month low of $9.20 and a 12-month high of $15.22.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.